But relapses are still frequent – a problem that, curiously, higher dosing has not assuaged.
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Several biotech stocks maintained throughout Asco the momentum they had going into the meeting, and intrigue over Tigit continued.
The company’s Tigit data are strong enough for a phase 3 trial to be launched, Asco learns.
In Trop2 Merck & Co might have got itself an ADC at least as good as Gilead and Astra/Daiichi’s leaders, for a fraction of the price.
An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.